995 studies found for:    Open Studies | "Carcinoma, Non-Small-Cell Lung"
Show Display Options
Rank Status Study
21 Recruiting Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Drug: Temoporfin;   Procedure: Therapeutic Conventional Surgery;   Drug: Photodynamic Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
22 Recruiting Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: hypofractionated radiation therapy;   Other: laboratory biomarker analysis;   Radiation: image-guided radiation therapy;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: stereotactic body radiation therapy
23 Not yet recruiting Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
Conditions: Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Other: medical chart review;   Other: laboratory biomarker analysis
24 Recruiting Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-paclitaxel IV;   Drug: CC-486
25 Recruiting Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Apatinib;   Drug: Placebo
26 Unknown  Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Erlotinib (Tarceva®)
27 Recruiting Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Afatinib Dimaleate;   Biological: Pembrolizumab
28 Recruiting Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Azacitidine;   Drug: Docetaxel;   Drug: Entinostat;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pemetrexed Disodium
29 Recruiting An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions: Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: stereotactic body radiation therapy;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: radiation therapy
30 Recruiting EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Navitoclax;   Drug: Osimertinib;   Other: Pharmacological Study
31 Recruiting Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Advanced Pleural Malignant Mesothelioma;   HLA-A*0201 Positive Cells Present;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pleural Mesothelioma
Interventions: Biological: Aldesleukin;   Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
32 Not yet recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
33 Not yet recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Osimertinib;   Other: Pharmacological Study;   Drug: Sapanisertib
34 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
35 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
36 Recruiting Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Abraxane (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
37 Not yet recruiting Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Interventions: Drug: Rociletinib;   Procedure: Biopsy;   Procedure: Blood draw
38 Recruiting Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Conditions: Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Other: cytology specimen collection procedure;   Procedure: therapeutic procedure;   Drug: targeted therapy;   Other: laboratory biomarker analysis
39 Recruiting Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: quinacrine dihydrochloride - Escalation dose;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Drug: quinacrine dihydrochloride - Extension dose
40 Unknown  Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: vinorelbine tartrate;   Drug: paclitaxel;   Procedure: quality-of-life assessment;   Other: questionnaire administration

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years